Termine
Performance
26.11.2021

24.11.21 Mister Spex SE
Publication quarterly statement (call-date Q3)
24.11.21 Geratherm Medical AG
Veröffentlichung Quartalsfinanzbericht (Stichtag Q3)
24.11.21 HomeToGo SE
Deutsche Börse AG: Deutsches Eigenkapitalforum 2021
24.11.21 Energy Recovery
Analystenveranstaltung
24.11.21 Accentro Real Estate AG
Roadshow
24.11.21 Instone Real Estate Group SE
Roadshow
24.11.21 ProCredit Holding AG & Co. KGaA
Analystenveranstaltung
24.11.21 EXASOL AG
Analystenveranstaltung
24.11.21 STRATEC SE
Analystenveranstaltung
24.11.21 STRATEC SE
Analysts' Conference
24.11.21 elumeo SE
Analystenveranstaltung
24.11.21 Viscom AG
Analystenveranstaltung
24.11.21 KAP AG
Veröffentlichung Quartalsmitteilung (Stichtag Q3)
24.11.21 Fyber N.V.
Veröffentlichung Quartalsmitteilung (Stichtag Q3)
24.11.21 Aroundtown SA
Veröffentlichung Quartalsfinanzbericht (Stichtag Q3)
24.11.21 CA IMMOBILIEN ANLAGEN AG
Zwischenbericht zum 3. Quartal 2021
24.11.21 HELMA Eigenheimbau AG
Analystenveranstaltung
24.11.21 paragon GmbH & Co. KGaA
Analysts' Conference
24.11.21 DFV Deutsche Familienversicherung AG
Analystenveranstaltung
24.11.21 Gesco AG
Analysts' Conference

November

KW M D M D F S S
44 1 2 3 4 5 6 7
45 8 9 10 11 12 13 14
46 15 16 17 18 19 20 21
47 22 23 24 25 26 27 28
48 29 30          

Dezember

KW M D M D F S S
48     1 2 3 4 5
49 6 7 8 9 10 11 12
50 13 14 15 16 17 18 19
51 20 21 22 23 24 25 26
52 27 28 29 30 31    

Januar 2022

KW M D M D F S S
52           1 2
1 3 4 5 6 7 8 9
2 10 11 12 13 14 15 16
3 17 18 19 20 21 22 23
4 24 25 26 27 28 29 30
5 31            

 

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

Aktuelle Research-Studie

3U HOLDING AG

Original-Research: 3U HOLDING AG (von GSC Research GmbH): Halten

26. November 2021